Life Science Nation Newsletter  | January 25,  2018  |  Issue 250

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
Life Science Investor Mandates (Jan. 18 - Jan. 24 )
Seeking Global Investment Opportunities in All Life Sciences Sectors
Seeks to In-License/Invest in Global Medical Device Innovations
Invests in Non-Invasive Devices and Healthcare IT Companies
Seeking USA-Based Orthopedic, Neurosurgical, and Gastroenterology Medical Device Companies
In This Issue
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Samuel Rubin, Business Development Manager, LSN

After receiving some excellent feedback from past applicants, the RESI Innovation Challenge Review Team has re-tooled the online application to create a standardized and efficient Sourcing & Ranking Expert System. For years LSN has been evaluating technologies for government organizations, large pharma, and other groups using this system to vet biotech, medtech, diagnostics, and healthcare IT companies based on their science and "invest-ability".

LSN believes the RESI Innovation Challenge application process will now be more logical and easier to navigate, streamlining the process from beginning to end. The application has now launched online. The deadline to apply for RESI on MaRS is Friday March 2nd. We look forward to reviewing all of your impressive applications!

By Lucy Parkinson, Director of Research, LSN

It's no surprise that pharma companies continue to make licensing deals at a rapid pace; in 2017, LSN's Licensing Deals platform on average logged one new deal every 3 days.  

Taking an overview of the data LSN gathered in this pacy year of dealmaking, we can see a few patterns emerging over the course of the year that show where pharma appetite is currently focused. (LSN's Licensing Deals platform only logs reported deals in which some financial information is available, whether it's an up-front payment or future milestones. Deals reported without any financial details are not included in our sample set. Corporate M&A activity isn't included either - just in-licensing). 

Deals Are Getting Earlier 

Some deals involved a research platform rather than a drug asset; however, in deals that involved a new drug, 2017 saw a substantial shift toward preclinical and Phase I opportunities...

By James Huang, Research Analyst, LSN

This year, I had the fortune and pleasure to both organize and sit in on the China Medtech Panel at RESI JPM. The four panelists from Guoqian Venture Capital, Button Capital, Elite Capital, and Unistone Ventures all provided great information and many new insights into how the Chinese markets work. What most stood out to me was their elucidation of key differences between China and the US that many entrepreneurs fail to see, and their explanation of how life science startups can best situate themselves to deal with these differences.

1. China's Markets Are Very Different from US Markets 

According to our RESI panelists, one cannot assume that the market in China is the same as the market in the US or other Western countries. Many companies think that they'll do great in China simply by running population metrics and not taking into account that China's health system functions very differently compared to Western countries. China's system has a different reimbursement process, China's hospitals are all state-run and follow a different ruleset, and the government plays a large part in pricing. As a result, many digital health companies based in the US and Europe have no market in China, and many other device and therapeutics companies that assume they have a large market in China may not actually have that market...

Created & Produced by

QuickFire Challenge
I n honor of the Grand Opening of JLABS @ NYC, Johnson & Johnson Innovation has launched a QuickFire Challenge to award up to four new game-changing early-stage innovation companies with the use of a bench, workstation and access to the JLABS @ NYC community for one year.

This competition will award the person or team(s) who submits the best idea, technology, or solution in the following areas:
  • Consumer healthcare
  • Health technologies
  • Medical devices
  • Therapeutics